Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397442 | 0.98 | CYP17A1 (0.44) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL6060901 | 0.93 | CYP17A1 (0.49) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL20397466 | 0.85 | CYP17A1 (0.46) | TBXAS1CYP17A1CYP19A1 | |
| SCHEMBL28417238 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL18885407 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL3851254 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL19611321 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL3421199 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL28566983 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL29220056 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3989920-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | Living Proof, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2020264257-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2020-12-30 | — | — | WO | claimed |
| EP-3651854-A1 | HETEROCYCLIC-DITHIOL CLICK CHEMISTRY | Northeastern University (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014311-A1 | HETEROCYCLIC-DITHIOL CLICK CHEMISTRY | NORTHEASTERN UNIVERSITY (US) | 2019-01-17 | — | — | WO | claimed |
| EP-2594248-A1 | Active ingredient combination and use thereof | Air Liquide Santé (International) (FR) | 2013-05-22 | — | — | EP | claimed |
| US-20100310487-A1 | ACTIVE INGREDIENT COMBINATION AND USE THEREOF | AIR LIQUIDE SANTE (INTERNATIONAL) (FR) | 2010-12-09 | — | — | US | claimed |
| EP-2257267-A2 | ACTIVE INGREDIENT COMBINATION AND USE THEREOF | Air Liquide Santé (International) (FR) | 2010-12-08 | — | — | EP | claimed |
| WO-2009106468-A2 | ACTIVE INGREDIENT COMBINATION AND USE THEREOF | AIR LIQUIDE SANTE (INTERNATIONAL) (FR) | 2009-09-03 | — | — | WO | claimed |
| EP-1301168-B1 | STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS | AIR LIQUIDE SANTE INT (FR) | 2007-08-01 | — | — | EP | claimed |
| EP-1806123-A2 | Storage-stable compositions of glycerol monoalkyl ethers | Air Liquide Santé (International) (FR) | 2007-07-11 | — | — | EP | claimed |
| US-20050238681-A1 | Storage-stable compositions of glycerol monoalkyl ethers | SCHULKE & MAYR GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| US-20030149097-A1 | Storage-stable compositions of glycerol monoalkyl ethers | ASHLAND SPECIALTIES DEUTSCHLAND GMBH (DE) | 2003-08-07 | — | — | US | claimed |
| EP-1301168-A1 | STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS | Air Liquide Santé (International) (FR) | 2003-04-16 | — | — | EP | claimed |
| WO-2001093825-A1 | STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS | AIR LIQUIDE SANTE (INTERNATIONAL) (FR) | 2001-12-13 | — | — | WO | claimed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| US-20250090435-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | SACHEM, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4376798-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | Sachem, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20050238681-A1 | Storage-stable compositions of glycerol monoalkyl ethers | SCHULKE & MAYR GMBH (DE) | 2005-10-27 | — | — | US | disclosed |
| US-6956062-B2 | Storage-stable compositions of glycerol monoalkyl ethers | Air Liquide Santé (International) (FR) | 2005-10-18 | — | — | US | disclosed |
| US-20030149097-A1 | Storage-stable compositions of glycerol monoalkyl ethers | ASHLAND SPECIALTIES DEUTSCHLAND GMBH (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090435-A1 | PRESERVATIVES FOR COSMETIC AND PHARMACEUTICAL COMPOSITIONS | PLOD2, CUTA, PHOSPHO1 | TBXAS1 2342/4885CYP17A1 61/4885CYP19A1 49/4885 |
| US-20100310487-A1 | ACTIVE INGREDIENT COMBINATION AND USE THEREOF | POLR1C, CUTA, CAT | TBXAS1 4832/4885CYP17A1 282/4885CYP19A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.